Trastuzumab for the treatment of HER2-positive metastatic gastric cancer

NICE technology appraisals [TA208] Published date:

NICE recommends trastuzumab as a possible treatment for some people (see below) with a type of HER2-positive metastatic gastric cancer called adenocarcinoma.

Who can have trastuzumab?

You should be able to have trastuzumab if:

  • you have a type of cancer that scores three when tested for HER2 and
  • you have not had treatment for metastatic gastric cancer before.

You can ask your healthcare professional to explain HER2 testing.

Get involved